Matthew Hart

Matthew Hart currently serves as a Scientist III in Tech Development for High Resolution Translational Immunology at the Allen Institute, a position held since September 2024. Previously, from January 2023 to October 2024, Matthew worked as a Scientist at RareCyte, Inc., focusing on indicators and risk factors associated with stillbirth during pregnancy using non-invasive liquid biopsy technology. Matthew has a substantial background in immunology, notably as a Staff Scientist at Fred Hutch, where research centered on T cell development for CAR T applications, and as a Senior Fellow at the University of Washington, investigating pre-B cell leukemia. Matthew's academic journey includes a PhD in Genetics from the University of Arizona, and postdoctoral studies in Cancer and Molecular Biology at the University of Washington. Matthew also contributed to significant research at the University of Arizona and gained early experience at Stanford University and the Allen Institute for Brain Science.